Skip to content
2000
Volume 21, Issue 1
  • ISSN: 2772-4328
  • E-ISSN: 2772-4336

Abstract

Examining antifungal resistance in dermatophytes is crucial in infectious diseases, dermatology, and clinical microbiology. The increasing occurrence of resistant infections and their influence on the effectiveness of therapy seem overwhelming. This study examines the present condition of antifungal resistance in dermatophytes, highlighting the need for ongoing and up-to-date research. Fungal diseases constantly change, and fungi have developed new resistance mechanisms. Here, we analyze the historical context of research on antifungal resistance, examining the variables that contribute to the development of resistance, such as the growing use of antifungals in clinical and agricultural contexts. We also explore the consequences of resistance to antifungal agents in clinical practice and public health. The review emphasizes the significance of new diagnostic technologies, like next-generation sequencing, in comprehending resistance mechanisms. It also underscores the crucial role of international collaboration in tackling this worldwide health concern. In conclusion, the paper emphasizes the need for continuous research to adjust to the evolving epidemiology of dermatophyte infections, create efficient treatment approaches, and guide public health interventions. This will ensure that the management of antifungal resistance is grounded in the most up-to-date scientific knowledge and optimal methods.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crcep/10.2174/0127724328328331241217194034
2025-01-30
2026-03-09

  • From This Site

    /content/journals/crcep/10.2174/0127724328328331241217194034
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WeitzmanI. SummerbellR.C. The dermatophytes.Clin. Microbiol. Rev.19958224025910.1128/CMR.8.2.240 7621400
     [Google Scholar]
  2. DurduM. IlkitM. Strategies to improve the diagnosis and clinical treatment of dermatophyte infections.Expert Rev. Anti Infect. Ther.202221 36329574
     [Google Scholar]
  3. ChepkwonyJ.K. MwitariP.G. KipsumbaiP.K. BiiC.C. TueiV.C. Anti-dermatophytic activity of Salvia nilotica methanolic crude leaf extract against Trichophyton mentagrophytes.J Phytopharmacol202110643343810.31254/phyto.2021.10602
     [Google Scholar]
  4. DengR. WangX. LiR. Dermatophyte infection: From fungal pathogenicity to host immune responses.Front. Immunol.202314128588710.3389/fimmu.2023.1285887 38022599
     [Google Scholar]
  5. MoskalukA.E. VandeWoudeS. Current topics in dermatophyte classification and clinical diagnosis.Pathogens202211995710.3390/pathogens11090957 36145389
     [Google Scholar]
  6. SunC. RenY. ZhangW. Association between skin disease and anxiety: A logistic analysis and prediction.Ann. Transl. Med.202311211510.21037/atm‑22‑6511 36819527
     [Google Scholar]
  7. JartarkarS.R. PatilA. GoldustY. Pathogenesis, immunology and management of dermatophytosis.J. Fungi2021813910.3390/jof8010039 35049979
     [Google Scholar]
  8. KruithoffC. GamalA. McCormickT.S. GhannoumM.A. Dermatophyte infections worldwide: Increase in incidence and associated antifungal resistance.Life2023141110.3390/life14010001 38276250
     [Google Scholar]
  9. SacheliR. HayetteM.P. Antifungal resistance in dermatophytes: Genetic considerations, clinical presentations and alternative therapies.J. Fungi202171198310.3390/jof7110983 34829270
     [Google Scholar]
  10. PaiV. GanavalliA. KikkeriN. Antifungal resistance in dermatology.Indian J. Dermatol.201863536136810.4103/ijd.IJD_131_17 30210155
     [Google Scholar]
  11. Martinez-RossiN.M. BitencourtT.A. PeresN.T.A. Dermatophyte resistance to antifungal drugs: Mechanisms and prospectus.Front. Microbiol.20189110810.3389/fmicb.2018.01108 29896175
     [Google Scholar]
  12. FangW. WuJ. ChengM. Diagnosis of invasive fungal infections: Challenges and recent developments.J. Biomed. Sci.20233014210.1186/s12929‑023‑00926‑2 37337179
     [Google Scholar]
  13. VermaS.B. PandaS. NenoffP. The unprecedented epidemic-like scenario of dermatophytosis in India: III. Antifungal resistance and treatment options.Indian J. Dermatol. Venereol. Leprol.202187446848210.25259/IJDVL_303_20 34219433
     [Google Scholar]
  14. Mota FernandesC. DasilvaD. HaranahalliK. The future of antifungal drug therapy: Novel compounds and targets.Antimicrob. Agents Chemother.2021652e01719e0172010.1128/AAC.01719‑20 33229427
     [Google Scholar]
  15. SalamM.A. Al-AminM.Y. SalamM.T. Antimicrobial resistance: A growing serious threat for global public health.Healthcare20231113194610.3390/healthcare11131946 37444780
     [Google Scholar]
  16. GuerrantR.L. WalkerD.H. WellerP.F. Tropical infectious diseases: Principles, pathogens and practice E-book: Principles, pathogens and practice (Expert consult - online and print).Elsevier Health Sciences2011
     [Google Scholar]
  17. KeshwaniaP. KaurN. ChauhanJ. Superficial dermatophytosis across the world’s populations: Potential benefits from nanocarrier-based therapies and rising challenges.ACS Omega2023835315753159910.1021/acsomega.3c01988 37692246
     [Google Scholar]
  18. PiresC.A.A. CruzN.F.S. LobatoA.M. SousaP.O. CarneiroF.R.O. MendesA.M.D. Clinical, epidemiological, and therapeutic profile of dermatophytosis.An. Bras. Dermatol.201489225926410.1590/abd1806‑4841.20142569 24770502
     [Google Scholar]
  19. SardanaK. GuptaA. MathachanS.R. Immunopathogenesis of dermatophytoses and factors leading to recalcitrant infections.Indian Dermatol. Online J.202112338939910.4103/idoj.IDOJ_503_20 34211904
     [Google Scholar]
  20. GargJ. TilakR. GargA. PrakashP. GulatiA. NathG. Rapid detection of dermatophytes from skin and hair.BMC Res. Notes2009216010.1186/1756‑0500‑2‑60 19374765
     [Google Scholar]
  21. BresciniL. FioritiS. MorroniG. BarchiesiF. Antifungal combinations in dermatophytes.J. Fungi20217972710.3390/jof7090727 34575765
     [Google Scholar]
  22. Martinez-RossiN.M. PeresN.T.A. BitencourtT.A. MartinsM.P. RossiA. State-of-the-art dermatophyte infections: Epidemiology aspects, pathophysiology, and resistance mechanisms.J. Fungi20217862910.3390/jof7080629 34436168
     [Google Scholar]
  23. YingY.H. LeeW.L. ChiY.C. ChenM.J. ChangK. Demographics, socioeconomic context, and the spread of infectious disease: The case of COVID-19.Int. J. Environ. Res. Public Health2022194220610.3390/ijerph19042206 35206390
     [Google Scholar]
  24. HavlickovaB. CzaikaV.A. FriedrichM. Epidemiological trends in skin mycoses worldwide.Mycoses200851s4Suppl. 421510.1111/j.1439‑0507.2008.01606.x 18783559
     [Google Scholar]
  25. ChanyachailertP. LeeyaphanC. BunyaratavejS. Cutaneous fungal infections caused by dermatophytes and non-dermatophytes: An updated comprehensive review of epidemiology, clinical presentations, and diagnostic testing.J. Fungi20239666910.3390/jof9060669 37367605
     [Google Scholar]
  26. UrbanK. ChuS. ScheufeleC. The global, regional, and national burden of fungal skin diseases in 195 countries and territories: A cross-sectional analysis from the global burden of disease study 2017.JAAD International20212222710.1016/j.jdin.2020.10.003 34409349
     [Google Scholar]
  27. DograS. UpretyS. The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive?Indian Dermatol. Online J.201672737610.4103/2229‑5178.178100 27057485
     [Google Scholar]
  28. VermaS.B. PandaS. NenoffP. The unprecedented epidemic-like scenario of dermatophytosis in India: I. Epidemiology, risk factors and clinical features.Indian J. Dermatol. Venereol. Leprol.202187215417510.25259/IJDVL_301_20 33769736
     [Google Scholar]
  29. CoulibalyO. L’OllivierC. PiarrouxR. RanqueS. Epidemiology of human dermatophytoses in Africa.Med. Mycol.201856214516110.1093/mmy/myx048 28992062
     [Google Scholar]
  30. TeklebirhanG. BitewA. Prevalence of dermatophytic infection and the spectrum of dermatophytes in patients attending a tertiary hospital in Addis Ababa, Ethiopia.Int. J. Microbiol.2015201565341910.1155/2015/653419 26448763
     [Google Scholar]
  31. LeeW.J. KimS.L. JangY.H. Increasing prevalence of trichophyton rubrum identified through an analysis of 115,846 cases over the last 37 years.J. Korean Med. Sci.201530563964310.3346/jkms.2015.30.5.639 25931797
     [Google Scholar]
  32. DurgadeviG PkK ShanthiG. Clinical profile of Tinea capitis among rural children in Cuddalore district.Int J Dermatol Venereol Leprol Sci202362 Part A0811
     [Google Scholar]
  33. SegalE. EladD. Human and zoonotic dermatophytoses: Epidemiological aspects.Front. Microbiol.20211271353210.3389/fmicb.2021.713532 34421872
     [Google Scholar]
  34. Rodríguez-CerdeiraC. Martínez-HerreraE. SzepietowskiJ.C. A systematic review of worldwide data on Tinea capitis: Analysis of the last 20 years.J. Eur. Acad. Dermatol. Venereol.202135484488310.1111/jdv.16951 32976663
     [Google Scholar]
  35. PetrucelliM.F. AbreuM.H. CantelliB.A.M. Epidemiology and diagnostic perspectives of dermatophytoses.J. Fungi20206431010.3390/jof6040310 33238603
     [Google Scholar]
  36. AlMaghrabiR.S. Al-MusawiT. AlbaksamiO. Challenges in the management of invasive fungal infections in the Middle East: expert opinion to optimize management using a multidisciplinary approach.Cureus2023158e4435610.7759/cureus.44356 37779746
     [Google Scholar]
  37. VanreppelenG. WuytsJ. Van DijckP. VandecruysP. Sources of antifungal drugs.J. Fungi20239217110.3390/jof9020171 36836286
     [Google Scholar]
  38. SiopiM. EfstathiouI. TheodoropoulosK. PournarasS. MeletiadisJ. Molecular epidemiology and antifungal susceptibility of trichophyton isolates in Greece: Emergence of terbinafine-resistant Trichophytonmentagrophytes type VIII locally and globally.J. Fungi20217641910.3390/jof7060419 34072049
     [Google Scholar]
  39. JiangY. LuoW. VerweijP.E. Regional differences in antifungal susceptibility of the prevalent dermatophyte trichophyton rubrum.Mycopathologia20211861537010.1007/s11046‑020‑00515‑z 33313977
     [Google Scholar]
  40. SinghA. MasihA. Monroy-NietoJ. A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile.Fungal Genet. Biol.201913310326610.1016/j.fgb.2019.103266 31491507
     [Google Scholar]
  41. NenoffP. VermaS.B. EbertA. Spread of terbinafine-resistant trichophyton mentagrophytes type VIII (India) in Germany–“The tip of the iceberg?”.J. Fungi20206420710.3390/jof6040207 33027904
     [Google Scholar]
  42. ShenJ.J. ArendrupM.C. VermaS. SaunteD.M.L. The emerging terbinafine-resistant trichophyton epidemic: What is the role of antifungal susceptibility testing?Dermatology20222381607910.1159/000515290 34058736
     [Google Scholar]
  43. VitielloA. FerraraF. BoccellinoM. Antifungal drug resistance: An emergent health threat.Biomedicines2023114106310.3390/biomedicines11041063 37189681
     [Google Scholar]
  44. WiederholdN. Antifungal resistance: Current trends and future strategies to combat.Infect. Drug Resist.20171024925910.2147/IDR.S124918 28919789
     [Google Scholar]
  45. AntonA. PlinetM. PeyretT. Rapid and accurate diagnosis of dermatophyte infections using the DendrisCHIP® technology.Diagnostics20231322343010.3390/diagnostics13223430 37998565
     [Google Scholar]
  46. DehghanP. ArammehrA. ChadeganipourM. KatoueezadehM. ShadziS. Detection of dermatophytes from dermatophytosis-suspected cases in Iran, evaluation of polymerase chain reaction-sequencing method.Adv. Biomed. Res.2020915610.4103/abr.abr_21_20 33457339
     [Google Scholar]
  47. GräserY. SaunteD. A hundred years of diagnosing superficial fungal infections: Where do we come from, where are we now and where would we like to go?Acta Derm. Venereol.20201009adv0011110.2340/00015555‑3467 32207536
     [Google Scholar]
  48. RogersT. VerweijP. CastanheiraM. Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.J. Antimicrob. Chemother.20227782053207310.1093/jac/dkac161
     [Google Scholar]
  49. NafeaA.M. WangY. WangD. Application of next-generation sequencing to identify different pathogens.Front. Microbiol.202414132933010.3389/fmicb.2023.1329330 38348304
     [Google Scholar]
  50. PospischilI. ReinhardtC. BontemsO. Identification of dermatophyte and non-dermatophyte agents in onychomycosis by PCR and DNA sequencing—a retrospective comparison of diagnostic tools.J. Fungi2022810101910.3390/jof8101019 36294584
     [Google Scholar]
  51. YamadaT. MaedaM. AlshahniM.M. Terbinafine resistance of trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene.Antimicrob. Agents Chemother.2017617e00115e0011710.1128/AAC.00115‑17 28416557
     [Google Scholar]
  52. VoljčM. Dermatophyte infections in humans: Current trends and future prospects.CRC Press2015327
     [Google Scholar]
  53. SatamH. JoshiK. MangroliaU. Next-generation sequencing technology: Current trends and advancements.Biology202312799710.3390/biology12070997 37508427
     [Google Scholar]
  54. Garcia-EffronG. Molecular markers of antifungal resistance: Potential uses in routine practice and future perspectives.J. Fungi20217319710.3390/jof7030197 33803304
     [Google Scholar]
  55. FisherM.C. Alastruey-IzquierdoA. BermanJ. Tackling the emerging threat of antifungal resistance to human health.Nat. Rev. Microbiol.202220955757110.1038/s41579‑022‑00720‑1 35352028
     [Google Scholar]
  56. Ayatollahi MousaviS.A. MokhtariA. BaraniM. Advances of liposomal mediated nanocarriers for the treatment of dermatophyte infections.Heliyon202398e1896010.1016/j.heliyon.2023.e18960 37583758
     [Google Scholar]
  57. OkekeI.N. IhekweazuC. The importance of molecular diagnostics for infectious diseases in low-resource settings.Nat. Rev. Microbiol.202119954754810.1038/s41579‑021‑00598‑5 34183821
     [Google Scholar]
  58. TaghipourS. ShamsizadehF. PchelinI. Emergence of terbinafine resistant Trichophyton mentagrophytes in Iran, harboring mutations in the squalene epoxidase (SQLE) gene.Infect. Drug Resist.20201384585010.2147/IDR.S246025 32214830
     [Google Scholar]
  59. AlabiP.E. GautierC. MurphyT.P. Small molecules restore azole activity against drug-tolerant and drug-resistant Candida isolates.MBio2023144e00479e2310.1128/mbio.00479‑23 37326546
     [Google Scholar]
  60. HossainC.M. RyanL.K. GeraM. Antifungals and drug resistance.Encyclopedia20222417221737
     [Google Scholar]
  61. BaoY. WanZ. LiR. In vitro antifungal activity of micafungin and caspofungin against dermatophytes isolated from China.Mycopathologia20131751-214114510.1007/s11046‑012‑9571‑6 22983900
     [Google Scholar]
  62. SuH. JiangW. VerweijP.E. The in vitro activity of echinocandins against clinical Trichophyton rubrum isolates and review of the susceptibility of T. rubrum to echinocandins worldwide.Infect. Drug Resist.2023165395540310.2147/IDR.S423735 37621698
     [Google Scholar]
  63. PoddarS. DasA. HayR.J. WollinaU. Newer therapies in dermatophytosis.Indian J. Dermatol.202368551551910.4103/ijd.ijd_829_23 38099134
     [Google Scholar]
  64. BelconM.C. Topical versus systemic antibiotics in the treatment of acute superficial skin infections.J. Natl. Med. Assoc.19797116364 423278
     [Google Scholar]
  65. MahajanR. SahooA.K. Management of tinea corporis, tinea cruris, and Tinea pedis: A comprehensive review.Indian Dermatol. Online J.201672778610.4103/2229‑5178.178099 27057486
     [Google Scholar]
  66. BayA. ÖnerA.F. EtlikÖ. ÇaksenH. A case of immune thrombocytopenic purpura presenting with recurrent intracranial hemorrhage.Pediatr. Int.200547110911110.1111/j.1442‑200x.2005.02014.x 15693880
     [Google Scholar]
  67. ZeichnerJ.A. New topical therapeutic options in the management of superficial fungal infections.J. Drugs Dermatol.20151410Suppl.s35s41 26461833
     [Google Scholar]
  68. WardH. ParkesN. SmithC. KluzekS. PearsonR. Consensus for the treatment of Tinea pedis: A systematic review of randomised controlled trials.J. Fungi20228435110.3390/jof8040351 35448582
     [Google Scholar]
  69. RajagopalanM. InamadarA. MittalA. Expert consensus on the management of dermatophytosis in India (ECTODERM India).BMC Dermatol.2018181610.1186/s12895‑018‑0073‑1 30041646
     [Google Scholar]
  70. HayR. Therapy of skin, hair and nail fungal infections.J. Fungi2018439910.3390/jof4030099 30127244
     [Google Scholar]
  71. ErikssonE. GriffithG.L. NuutilaK. Topical drug delivery in the treatment of skin wounds and ocular trauma using the platform wound device.Pharmaceutics2023154106010.3390/pharmaceutics15041060 37111546
     [Google Scholar]
  72. KardasP. LewekP. MatyjaszczykM. Determinants of patient adherence: A review of systematic reviews.Front. Pharmacol.201349110.3389/fphar.2013.00091 23898295
     [Google Scholar]
  73. KvarnströmK. WesterholmA. AiraksinenM. LiiraH. Factors contributing to medication adherence in patients with a chronic condition: A scoping review of qualitative research.Pharmaceutics2021137110010.3390/pharmaceutics13071100 34371791
     [Google Scholar]
  74. Vahedi-ShahandashtiR. Lass-FlörlC. Novel antifungal agents and their activity against Aspergillus species.J. Fungi20206421310.3390/jof6040213 33050302
     [Google Scholar]
  75. SzymańskiM. ChmielewskaS. CzyżewskaU. MalinowskaM. TylickiA. Echinocandins – Structure, mechanism of action and use in antifungal therapy.J. Enzyme Inhib. Med. Chem.202237187689410.1080/14756366.2022.2050224 35296203
     [Google Scholar]
  76. IvanovM. ĆirićA. StojkovićD. Emerging antifungal targets and strategies.Int. J. Mol. Sci.2022235275610.3390/ijms23052756 35269898
     [Google Scholar]
  77. NamiS. Aghebati-MalekiA. Aghebati-MalekiL. Current applications and prospects of nanoparticles for antifungal drug delivery.EXCLI J.202120562584 33883983
     [Google Scholar]
  78. BilaN.M. Costa-OrlandiC.B. VasoC.O. 2-Hydroxychalcone as a potent compound and photosensitizer against dermatophyte biofilms.Front. Cell. Infect. Microbiol.20211167947010.3389/fcimb.2021.679470 34055673
     [Google Scholar]
  79. LyonJ.P. de Maria Pedroso e Silva AzevedoC. MoreiraL.M. de LimaC.J. de ResendeM.A. Photodynamic antifungal therapy against chromoblastomycosis.Mycopathologia2011172429329710.1007/s11046‑011‑9434‑6 21643843
     [Google Scholar]
  80. MehtaD. SainiV. BajajA. Recent developments in membrane targeting antifungal agents to mitigate antifungal resistance.RSC Med. Chem.20231491603162810.1039/D3MD00151B 37731690
     [Google Scholar]
  81. SousaF. FerreiraD. ReisS. CostaP. Current insights on antifungal therapy: Novel nanotechnology approaches for drug delivery systems and new drugs from natural sources.Pharmaceuticals202013924810.3390/ph13090248 32942693
     [Google Scholar]
  82. WuX. HuY. Photodynamic therapy for the treatment of fungal infections.Infect. Drug Resist.2022153251326610.2147/IDR.S369605 35761978
     [Google Scholar]
  83. VaouN. StavropoulouE. VoidarouC. TsigalouC. BezirtzoglouE. Towards advances in medicinal plant antimicrobial activity: A review study on challenges and future perspectives.Microorganisms2021910204110.3390/microorganisms9102041 34683362
     [Google Scholar]
  84. RexJ.H. PfallerM.A. GalgianiJ.N. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for Fluconazole, Itraconazole, and Candida infections.Clin. Infect. Dis.199724223524710.1093/clinids/24.2.235 9114154
     [Google Scholar]
  85. CzajkaK.M. VenkataramanK. Brabant-KirwanD. Molecular mechanisms associated with antifungal resistance in pathogenic Candida species.Cells20231222265510.3390/cells12222655 37998390
     [Google Scholar]
  86. MaliR. PatilJ. Nanoparticles: A novel antifungal drug delivery system.Mater Proc202314161
     [Google Scholar]
  87. HassounN. KassemI.I. HamzeM. El TomJ. PaponN. OsmanM. Antifungal use and resistance in a lower–middle-income country: The case of Lebanon.Antibiotics2023129141310.3390/antibiotics12091413 37760710
     [Google Scholar]
  88. OhmannC. BanziR. CanhamS. Sharing and reuse of individual participant data from clinical trials: Principles and recommendations.BMJ Open2017712e01864710.1136/bmjopen‑2017‑018647 29247106
     [Google Scholar]
  89. GhannoumM. Azole resistance in dermatophytes.J. Am. Podiatr. Med. Assoc.20161061798610.7547/14‑109 26895366
     [Google Scholar]
  90. BlanchardG. AmarovB. FrattiM. Reliable and rapid identification of terbinafine resistance in dermatophytic nail and skin infections.J. Eur. Acad. Dermatol. Venereol.202337102080208910.1111/jdv.19253 37319111
     [Google Scholar]
  91. EbertA. MonodM. SalaminK. Alarming India‐wide phenomenon of antifungal resistance in dermatophytes: A multicentre study.Mycoses202063771772810.1111/myc.13091 32301159
     [Google Scholar]
  92. MahajanS. TilakR. KaushalS. MishraR. PandeyS. Clinico-mycological study of dermatophytic infections and their sensitivity to antifungal drugs in a tertiary care center.Indian J. Dermatol. Venereol. Leprol.201783443644010.4103/ijdvl.IJDVL_519_16 28540871
     [Google Scholar]
  93. Van TroC. Ho Thi NgocK. Nguyen VanT. Antifungal susceptibility of dermatophytes isolated from cutaneous fungal infections: The Vietnamese experience.Open Access Maced. J. Med. Sci.20197224724910.3889/oamjms.2019.062 30745971
     [Google Scholar]
  94. GohC.L. TayY.K. Bin AliK. KohM.T. SeowC.S. In vitro evaluation of griseofulvin, ketoconazole, and itraconazole against various dermatophytes in Singapore.Int. J. Dermatol.1994331073373710.1111/j.1365‑4362.1994.tb01523.x 8002147
     [Google Scholar]
  95. KhalifaH.O. AraiT. MajimaH. WatanabeA. KameiK. Genetic basis of azole and echinocandin resistance in clinical Candida glabrata in Japan.Antimicrob. Agents Chemother.2020649e00783e2010.1128/AAC.00783‑20 32571826
     [Google Scholar]
  96. NaickerS.D. ShupingL. ZuluT.G. Epidemiology and susceptibility of Nakaseomyces (formerly Candida) glabrata bloodstream isolates from hospitalised adults in South Africa.Med. Mycol.2023616myad05710.1093/mmy/myad057 37336590
     [Google Scholar]
/content/journals/crcep/10.2174/0127724328328331241217194034
Loading
Breaking the Mold: Advances and Hurdles in Antifungal Resistance Management for Dermatophytes
Curr Rev Clin Exper Pharm 21, 12 (2026); https://doi.org/10.2174/0127724328328331241217194034
/content/journals/crcep/10.2174/0127724328328331241217194034
/content/journals/crcep/10.2174/0127724328328331241217194034
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): agriculture; Antifungal resistance; clinical microbiology; dermatophytes; infectious diseases; public health

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test